New epilepsy treatment demonstrates UCB's leadership
Posted by
20-Jan-2016
Here at UCB we pride ourselves on playing a leadership role in improving the lives of people with epilepsy.
The onus is on leaders to take responsibility for solving difficult problems in their areas of expertise and we never shy away from a challenge.
We are not satisfied with the status quo; we listen to the epilepsy community and strive to tackle the unmet medical needs highlighted by patients and health professionals.
One of the biggest challenges in epilepsy is the large number of people whose symptoms are not well managed. It is estimated that more than 30% of the 65 million people worldwide with epilepsy are resistant to treatments currently available.
When we see the profound impact successful therapy can have on people living with epilepsy, it inspires us to redouble our efforts to bring the same benefits to those for whom current medicines are ineffective.
By investing in science, UCB constantly searches for innovative treatments that would give patients and health professionals more tools for tackling seizures.
This requires time and, of course, financial commitment. Not every promising compound makes it from the lab to the patient. In fact, most potential new treatments do not clear all the clinical and regulatory hurdles required.
That is why it is so satisfying to see our newest epilepsy drug, BRIVIACT® (brivaracetam), given the green light by the European Commission after receiving a positive recommendation from the European Medicines Agency.
BRIVIACT® is approved as an adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization (spreading to both sides of the brain after the initial seizure) in adult and adolescent patients from 16 years of age with epilepsy.
This welcome news offers more treatment choice for people with epilepsy and illustrates UCB’s commitment to playing a leadership role in the epilepsy community.
The onus is on leaders to take responsibility for solving difficult problems in their areas of expertise and we never shy away from a challenge.
We are not satisfied with the status quo; we listen to the epilepsy community and strive to tackle the unmet medical needs highlighted by patients and health professionals.
One of the biggest challenges in epilepsy is the large number of people whose symptoms are not well managed. It is estimated that more than 30% of the 65 million people worldwide with epilepsy are resistant to treatments currently available.
When we see the profound impact successful therapy can have on people living with epilepsy, it inspires us to redouble our efforts to bring the same benefits to those for whom current medicines are ineffective.
By investing in science, UCB constantly searches for innovative treatments that would give patients and health professionals more tools for tackling seizures.
This requires time and, of course, financial commitment. Not every promising compound makes it from the lab to the patient. In fact, most potential new treatments do not clear all the clinical and regulatory hurdles required.
That is why it is so satisfying to see our newest epilepsy drug, BRIVIACT® (brivaracetam), given the green light by the European Commission after receiving a positive recommendation from the European Medicines Agency.
BRIVIACT® is approved as an adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization (spreading to both sides of the brain after the initial seizure) in adult and adolescent patients from 16 years of age with epilepsy.
This welcome news offers more treatment choice for people with epilepsy and illustrates UCB’s commitment to playing a leadership role in the epilepsy community.
Leave a Comment